Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

This Phase II clinical trial explores whether a combination of two drugs, amivantamab and hyaluronidase, is as effective as the standard treatment, cetuximab, for advanced skin cancer. Specifically, the study focuses on cutaneous squamous cell carcinoma that has either returned in the same area or spread to other parts of the body. Both amivantamab and cetuximab are a type of protein called monoclonal antibodies, which are designed to find and block signals that cancer cells use to grow. The addition of hyaluronidase aims to help amivantamab stay in the body longer to increase its impact.

This study is specifically looking for participants who have a weakened immune system. This includes people with certain blood cancers (like CLL or lymphoma), organ transplant recipients, or those taking immunosuppressant medications for an autoimmune disease like rheumatoid arthritis or lupus. To join, your cancer must be advanced enough that surgery or radiation are no longer the best options. You should not have received cetuximab or a similar drug in the past year.

If you participate, you will be assigned to receive either the amivantamab combination or cetuximab. These treatments are given as injections under the skin or through an IV infusion. You will also have regular blood tests and imaging scans, such as CT or MRI, to monitor your health and see how the cancer responds. Before enrolling, talk with your doctor about your immune system history, your current medications, and any past lung or heart conditions to ensure this study is a safe option for you.